Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.

Berger KL, Sarrazin C, Nelson DR, Scherer J, Sha N, Marquis M, Côté-Martin A, Vinisko R, Stern JO, Mensa FJ, Kukolj G.

PLoS One. 2016 Aug 5;11(8):e0160668. doi: 10.1371/journal.pone.0160668. eCollection 2016.

2.

Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.

Nishiguchi S, Urano Y, Suzaki K, Taniguchi A, Scherer J, Berger KL, Quinson AM, Stern JO, Omata M.

Hepatol Res. 2017 Mar;47(3):E142-E151. doi: 10.1111/hepr.12741. Epub 2016 Aug 10.

PMID:
27153246
3.

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.

Chukkapalli V, Berger KL, Kelly SM, Thomas M, Deiters A, Randall G.

Virology. 2015 Feb;476:168-179. doi: 10.1016/j.virol.2014.12.018. Epub 2014 Dec 26.

4.

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.

Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Böcher WO, Datsenko Y, Steinmann G, Scherer J, Stern JO, Kukolj G.

Antimicrob Agents Chemother. 2014;58(2):698-705. doi: 10.1128/AAC.01976-13. Epub 2013 Nov 11.

5.

Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.

Berger KL, Lagacé L, Triki I, Cartier M, Marquis M, Lawetz C, Bethell R, Scherer J, Kukolj G.

Antimicrob Agents Chemother. 2013 Oct;57(10):4928-36. doi: 10.1128/AAC.00822-13. Epub 2013 Jul 22.

6.

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group.

Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. doi: 10.1128/AAC.00565-13. Epub 2013 Jul 15.

7.

Molecular determinants and dynamics of hepatitis C virus secretion.

Coller KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, Randall G.

PLoS Pathog. 2012 Jan;8(1):e1002466. doi: 10.1371/journal.ppat.1002466. Epub 2012 Jan 5.

8.

Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.

Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G.

J Virol. 2011 Sep;85(17):8870-83. doi: 10.1128/JVI.00059-11. Epub 2011 Jun 22.

9.

Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis.

Heaton NS, Perera R, Berger KL, Khadka S, Lacount DJ, Kuhn RJ, Randall G.

Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17345-50. doi: 10.1073/pnas.1010811107. Epub 2010 Sep 20.

10.

Possibilities for RNA interference in developing hepatitis C virus therapeutics.

Berger KL, Randall G.

Viruses. 2010 Aug;2(8):1647-65. doi: 10.3390/v2081647. Epub 2010 Aug 6.

11.
12.

RNA interference and single particle tracking analysis of hepatitis C virus endocytosis.

Coller KE, Berger KL, Heaton NS, Cooper JD, Yoon R, Randall G.

PLoS Pathog. 2009 Dec;5(12):e1000702. doi: 10.1371/journal.ppat.1000702. Epub 2009 Dec 24.

13.

Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication.

Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7577-82. doi: 10.1073/pnas.0902693106. Epub 2009 Apr 17.

14.

Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras.

Berger KL, Barriga F, Lace MJ, Turek LP, Zamba GJ, Domann FE, Lee JH, Klingelhutz AJ.

Virology. 2006 Dec 5-20;356(1-2):68-78. Epub 2006 Aug 30.

15.

Propagation of infectious human papillomavirus type 16 by using an adenovirus and Cre/LoxP mechanism.

Lee JH, Yi SM, Anderson ME, Berger KL, Welsh MJ, Klingelhutz AJ, Ozbun MA.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2094-9. Epub 2004 Feb 9.

16.

Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomes.

Sprague DL, Phillips SL, Mitchell CJ, Berger KL, Lace M, Turek LP, Klingelhutz AJ.

Virology. 2002 Sep 30;301(2):247-54.

Supplemental Content

Loading ...
Support Center